Aktienanalyse zu Schrodinger Inc (SDGR)SDGRSchrodinger Inc

Schrodinger, Inc. is a developer of a physics-based computational platform that enables discovery of molecules for drug development and materials applications. The Company's segments include Software and Drug Discovery. The Software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in the material science industries. The Drug Discovery segment is focused on building a portfolio of preclinical and clinical drug programs, internally and through collaborations. It offers WaterMap, which characterizes the locations and energetics of water molecules occupying the binding site of, or solvating, a target protein. It also offers FEP+, which is a free energy calculation software which can be used to replace the central core of earlier known tight binding molecules to identify potent molecules unavailable in library collections. It can also be used to calculate absolute binding affinities. It operates in the Technology sector (PHARMACEUTICAL PREPARATIONS industry).

Currently, Schrodinger Inc (SDGR) is trading at $22.60, which is above the average analyst target price of $21.43, indicating some positive sentiment. However, the RSI is at a low 21.619, suggesting the stock is oversold and could rebound, but the recent 5-day change of -17.16% raises concerns. The main risk is the insider selling, which has increased by 609.71% over the last month, indicating potential lack of confidence from those within the company.